Anemia
Drug research and approvals for anemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 510 studies of anemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 41 drug trials for it since 2013, FDA has 22 approved and 34 open orphan designations naming it, and the EU has 13 authorised medicines for it.
- Recruiting worldwide: 510
- Trials authorized in Canada: 41
- FDA orphan approvals: 22
- EU medicines: 13
- A Phase 3 Evaluation of Sutacimig in Glanzmann ThrombastheniaNCT07935356 · Phase 3 · Hemab ApS · starts Oct 27, 2026
- Aplastic Anemia Life-Course Cohort StudyNCT07930793 · Not reported · Institute of Hematology & Blood Diseases Hospital, China · starts Jan 1, 2012
- Iron Treatment for Iron Deficiency Anemia in Children and Young Adults With Crohn's DiseaseNCT07925450 · Phase 4 · Weill Medical College of Cornell University · starts Sep 13, 2023
- Safety and Tolerability of Metformin and Naproxen for Cancer Prevention in Fanconi AnemiaNCT07901959 · Phase 1 · Rockefeller University · starts Oct 14, 2026
- Neonatal Outcomes on Direct Fetal Intravenous Immunoglobulin During Intrauterine Transfusion for Rhesus IsoimmunizationNCT07885592 · Phase 2 · Post Graduate Institute of Medical Education and Research, Chandigarh · starts May 25, 2026
- Combination Therapy With Danazol, Prednisolone, and Thalidomide for Thalidomide-Refractory Transfusion-Dependent…NCT07884773 · Phase 3 · Khyber Medical University Peshawar · starts Oct 12, 2026
- Safety and Efficacy of Iron Prophylaxis With on Iron Homeostasis in Healthy Pregnant WomenNCT07884617 · Not applicable · IBSA Farmaceutici Italia Srl · starts May 18, 2026
- Mother and Offspring's Nutritional Status -Pregnancy After Maternal Bariatric SurgeryNCT07877233 · Not reported · Helse Nord-Trøndelag HF · starts Dec 25, 2025
- Empowering the Clinical Management of BMFs Through a Biological and Genetically Driven Pediatric and Adult National…NCT07877727 · Not reported · Istituto Giannina Gaslini · starts May 29, 2025
Approved 24 of 57
- Epoetin alfaErythropoietin receptor agonist
- Epoetin betaErythropoietin receptor agonist
- Darbepoetin alfaErythropoietin receptor agonist
- DaprodustatHypoxia-inducible factor prolyl hydroxylase inhibitor
- Methoxy polyethylene glycol-epoetin betaErythropoietin receptor agonist
- Ferric carboxymaltoseSupplement
- RoxadustatHypoxia-inducible factor prolyl hydroxylase inhibitor
- Iron sucroseSupplement
- Ferumoxytol
- Iron dextranSupplement
- Ascorbic acidSupplement
- LuspaterceptTransforming growth factor beta inhibitor
- CyanocobalaminSupplement
- Folic acid
- VadadustatEgl nine homolog 1 inhibitor
- LenalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- Ferric derisomaltoseSupplement
- Biotin
- CladribineDNA inhibitor
- FelbamateGlutamate [NMDA] receptor antagonist
- PentostatinAdenosine deaminase inhibitor
- VoxelotorHemoglobin HbA positive modulator
- ImigluceraseGlucocerebroside hydrolytic enzyme
- Zinc oxideSunscreen/skin protectant
Phase 3 12 of 18
- Polyethylene glycolOsmotic laxative
- PeginesatideErythropoietin receptor agonist
- CisplatinDNA inhibitor
- PyrimethamineDihydrofolate reductase inhibitor
- SulfadoxineDihydropteroate synthetase inhibitor
- MebendazoleTubulin inhibitor
- CarboplatinDNA inhibitor
- DiclofenacCyclooxygenase inhibitor
- PaclitaxelTubulin inhibitor
- Tranexamic acidPlasminogen inhibitor
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- DexamethasoneGlucocorticoid receptor agonist
Phase 2 12 of 15
- SotaterceptInhibin beta A chain inhibitor
- DeferasiroxIron chelating agent
- Lexaptepid pegol
- Salsalate
- SirolimusFK506-binding protein 1A inhibitor
- NitroprussideSoluble guanylate cyclase activator
- TretinoinRetinoic acid receptor agonist
- RuxolitinibTyrosine-protein kinase JAK1 inhibitor
- AcetylcholineMuscarinic acetylcholine receptor M3 agonist
- TilarginineNitric oxide synthase inhibitor
- Blood, whole
- MolidustatEgl nine homolog 1 inhibitor
Phase 1 or earlier 12 of 25
- MoxifloxacinTopoisomerase IV inhibitor
- AlemtuzumabCAMPATH-1 antigen inhibitor
- BusulfanDNA inhibitor
- EltrombopagThrombopoietin receptor agonist
- Fludarabine
- FlurbiprofenCyclooxygenase inhibitor
- MidazolamGABA-A receptor; anion channel positive allosteric modulator
- PhenytoinSodium channel alpha subunit blocker
- PioglitazonePeroxisome proliferator-activated receptor gamma agonist
- RosiglitazonePeroxisome proliferator-activated receptor gamma agonist
- ThiotepaDNA inhibitor
- GemfibrozilPeroxisome proliferator-activated receptor alpha agonist
How its trials ended
1,685 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 481 whose ending is known, 49% met their primary endpoint, 7% missed it and 44% stopped early.
- Completed, result not reported72243%
- Ongoing28517%
- Met its primary endpoint23514%
- Status unknown19712%
- Stopped: other or unclear996%
- Stopped: enrollment or feasibility644%
- Missed its primary endpoint362%
- Stopped: sponsor or business decision251%
- Stopped: lack of efficacy161%
- Stopped: funding4<1%
- Stopped: safety2<1%
| Nov 13, 2026 | A phase 1, randomized, double-blinded, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and…EPRA-0322 | Epok Therapeutics Inc. | Pending |
| Jul 22, 2026 | A phase 3, double-blind, randomized trial evaluating the efficacy and safety of elritercept (TAK-226) compared to placebo in participants with myelofibrosis…Elritercept (TAK-226, KER-050) | Takeda Pharmaceuticals USA | Pending |
| Dec 9, 2025 | A phase 2/3 randomized, multicenter study of osivelotor administered orally to adult and adolescent participants with sickle cell diseaseOsivelotor (PF-07940367, GBT021601) | Pfizer | Pending |
| May 7, 2025 | A randomized, double-blind, placebo-controlled, first-in-human study of the safety, tolerability, pharmacokinetics, and preliminary efficacy of aln-cfb, an…Aln-cfb (ALN-1725763) | Regeneron | Ongoing |
| Mar 24, 2025 | A phase 2, randomized, open-label, study of momelotinib in participants with anemia due to low-risk myelodysplastic syndromeMomelotinib (GSK3070785) | GSK | Ongoing |
| Jun 17, 2024 | A phase III randomized trial comparing unrelated donor bone marrow transplantation with immune suppressive therapy for newly diagnosed pediatric and young…Fludarabine | National Marrow Donor Program | Closed |
| May 22, 2024 | Optima study : optimizing hydroxyurea dosage with pharmakokinetic in patients suffering of moderate to severe sickle cell anemia.Hydroxyurea | Dr. Yves Pastore | Ongoing |
| Nov 8, 2023 | The effect of intravenous iron in treating anemia in ovarian cancer patients in saskatchewan: a phase-iii, open-label, randomized trialIron | University of Saskatchewan | Closed |
| Aug 28, 2023 | A phase 1/2, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral nuvisertib (TP-3654) in patients with intermediate or…Nuvisertib (TP-3654) / Momelotinib | Sumitomo Pharma | Pending |
| Jun 30, 2023 | A phase 3, open-label, randomized study to compare the efficacy and safety of luspatercept (ACE-536) vs epoetin alfa for the treatment of anemia due to revised…Luspatercept (ace 536) / Epoetin alfa | Bristol-Myers Squibb | Ongoing |
| Aug 24, 2026 | ImaavyTreatment of warm autoimmune hemolytic anemia (wAIHA) in adult and pediatric patients 12 years of age and older currently or previously… | Janssen Research & Development, LLC | Approved |
| Dec 23, 2025 | AqvesmeTreatment of anemia in adults with alpha- or beta-thalassemia | Agios Pharmaceuticals, Inc. | Approved |
| Dec 5, 2025 | OmisirgeTreatment of adults and pediatric patients 6 years of age and older with severe aplastic anemia (SAA) following reduced intensity… | Gamida Cell Ltd. | Approved |
| Dec 23, 2024 | XromiTo reduce the frequency of painful crises and reduce the need for blood transfusions in pediatric patients 6 months of age and older with… | Nova Laboratories Limited | Approved |
| Jun 6, 2024 | RyteloTreatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4… | Geron Corporation | Approved |
| Apr 4, 2024 | XromiTo reduce the frequency of painful crises and reduce the need for blood transfusions in pediatric patients aged 6 months of age to less… | Nova Laboratories Limited | Approved |
| Sep 15, 2023 | OjjaaraTreatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and… | GlaxoSmithKline | Approved |
| Aug 28, 2023 | ReblozylTreatment of anemia without previous erythropoiesis stimulating agent use (ESA-naive) in adult patients with very low- to intermediate-risk… | Celgene Corporation, a Bristol-Myers Squibb Company | Approved |
| Jan 25, 2023 | EnjaymoTreatment of hemolysis in adults with cold agglutinin disease (CAD) | Recordati Rare Diseases Inc. | Approved |
| Feb 17, 2022 | PyrukyndTreatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency | Agios Pharmaceuticals, Inc. | Approved |
| Feb 4, 2022 | EnjaymoTo decrease the need for red blood cell (RBC) transfusion due to hemolysis in adults with cold agglutinin disease (CAD) | Recordati Rare Diseases Inc. | Approved |
| Apr 3, 2020 | ReblozylREBLOZYL is indicated for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units… | Celgene Corporation, a Bristol-Myers Squibb Company | Approved |
| Nov 8, 2019 | ReblozylREBLOZYL is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC)… | Celgene Corporation | Approved |
| Nov 16, 2018 | PromactaPROMACTA is indicated in combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients 2… | Novartis Pharmaceuticals Corp. | Approved |
| Dec 21, 2017 | SiklosTo reduce the frequency of painful crises and to reduce the need for blood transfusions in pediatric patients, 2 years of age and older,… | Theravia Pharma | Approved |
| Mar 7, 2025 | RyteloImetelstat · orphan | Geron Netherlands B.V. | EMA ↗ |
| Aug 18, 2021 | EvrenzoRoxadustat | Astellas Pharma Europe B.V. | EMA ↗ |
| Jun 25, 2020 | ReblozylLuspatercept · orphan | Bristol Myers Squibb Pharma EEIG | EMA ↗ |
| Jul 1, 2019 | XromiHydroxycarbamide | Lipomed GmbH | EMA ↗ |
| Feb 18, 2016 | FeraccruFerric maltol | Norgine B.V. | EMA ↗ |
| Dec 18, 2007 | SilapoEpoetin zeta · biosimilar | Stada Arzneimittel AG | EMA ↗ |
| Dec 18, 2007 | RetacritEpoetin zeta · biosimilar | Pfizer Europe MA EEIG | EMA ↗ |
| Aug 28, 2007 | BinocritEpoetin alfa · biosimilar | Sandoz GmbH | EMA ↗ |
| Aug 27, 2007 | Epoetin Alfa HexalEpoetin alfa · biosimilar | Hexal AG | EMA ↗ |
| Aug 27, 2007 | AbseamedEpoetin alfa · biosimilar | Medice Arzneimittel Pütter GmbH Co. KG | EMA ↗ |
| Jul 20, 2007 | MirceraMethoxy polyethylene glycol-epoetin beta | Roche Registration GmbH | EMA ↗ |
| Jun 29, 2007 | SiklosHydroxycarbamide | Theravia | EMA ↗ |
| Jun 8, 2001 | AranespDarbepoetin alfa | Amgen Europe B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA